Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-viral antisense therapies - Mateon Therapeutics

Drug Profile

Research programme: anti-viral antisense therapies - Mateon Therapeutics

Latest Information Update: 12 Mar 2020

At a glance

  • Originator Mateon Therapeutics
  • Class Antisense elements; Antivirals; Oligonucleotides
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections; Viral infections

Highest Development Phases

  • Research COVID 2019 infections; Viral infections

Most Recent Events

  • 02 Mar 2020 Research programme: anti-viral antisense therapies - Mateon Therapeutics is available for licensing as of 02 Mar 2020. https://www.oncotelic.com/
  • 02 Mar 2020 Early research in COVID-2019 infections in USA (Parenteral)
  • 02 Mar 2020 Early research in Viral infections in USA (Parenteral)

Development Overview

Introduction

Mateon Therapeutics is developing antisense oligonucleotides for the treatment of coronavirus infectious disease (COVID-2019) as well as other viral diseases occurring due to zoonotic viruses; under a rapid antiviral response programme. The company will develop the therapeutics using its artificial intelligence platform; EdgePoint which processes machine learning models. Early research is underway in the US.

The antisense programme which is being developed under Rapid Antiviral Response Program will be modeled after the ongoing EdgePoint AI development model at Mateon. After developing and establishing the technology, Mateon plans to form a separate company or sell the technology and the programme to a larger entity for further development.

Key Development Milestones

In March 2020, Mateon Therapeutics reported that it is evaluating the potential of its AI Vision technology to help monitor patients infected with the COVID-19 virus, or any other viruses. Mateon Therapeutics reported that its two additional therapeutic oligonucleotides designed to target COVID-19, demonstrated potent antiviral activity. These candidates were all designed to work synergistically to avoid resistant mutations frequently seen with viral infections. They inhibited virus binding to its target, thereby stopping the virus from replicating itself and stopping viral induced pneumonia, which often leads to patient complications [1] [2] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Antisense elements, Antivirals, Oligonucleotides
  • Target Virus replication
  • Mechanism of Action Virus replication inhibitors
  • WHO ATC code

    J05A-X (Other antivirals)

  • EPhMRA code

    J5B (Antivirals, excluding anti-HIV products)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research USA Parenteral / unspecified Mateon Therapeutics 02 Mar 2020
Viral infections - - Research USA Parenteral / unspecified Mateon Therapeutics 02 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Mateon Therapeutics Originator USA
Mateon Therapeutics Owner USA

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Mateon Therapeutics COVID 2019 infections, Viral infections Unspecified - 02 Mar 2020

Development History

Event Date Update Type Comment
02 Mar 2020 Licensing Status Research programme: anti-viral antisense therapies - Mateon Therapeutics is available for licensing as of 02 Mar 2020. https://www.oncotelic.com/ Updated 12 Mar 2020
02 Mar 2020 Phase Change Early research in COVID-2019 infections in USA (Parenteral) [2] Updated 06 Mar 2020
02 Mar 2020 Phase Change Early research in Viral infections in USA (Parenteral) [2] Updated 06 Mar 2020

References

  1. Mateon Report Positive Results for Multiple COVID-19 Drug Candidates.

    Media Release
  2. Mateon Provides Update on its Rapid Antiviral Response Program Initially Targeting COVID-19.

    Media Release
Back to top